Optimi Health Corp. announced the appointment of Dr. Preston A. Chase as the Company?s Chief Science Officer (CSO). Dr. Chase is a distinguished Research & Development chemist and seasoned business professional with an impressive academic and industrial track record spanning over 25 years.

His extensive experience includes pioneering the development and commercialization of innovative products and processes for both multinational corporations and startup ventures. He holds a BSc from the University of Victoria and a PhD from the University of Calgary, and a solid foundation in catalysis, synthesis, and analytical chemistry. With over 30 peer-reviewed scientific publications and numerous awarded and pending patents, he brings a wealth of research expertise and a strong history of commercial success to the Optimi Health team.

In his new role, Dr. Chase will take charge of shaping and advancing research capabilities and delivering safe, effective products to the nascent psychedelic market. His mandate includes the critical task of establishing the scientific validity and utility of Optimi's GMP psilocybin and MDMA drug candidates while fostering transparent communication with scientific and customer communities. He will also lead a core scientific team throughout the development process, ensuring that the Company continues to push the boundaries of innovation.

Further, his experience in analysis of botanicals for medical use will support the integrity of Optimi?s drug candidates and the robustness of the Company?s supply pathway, ensuring that Optimi meets the higher standards of quality assurance and regulatory compliance in cultivation and dose factor for its customers. As Dr. Chase assumes leadership of Optimi's R&D and science-driven protocols, the Company extends its appreciation to Justin Kirkland, the departing CSO, for his devoted service to Optimi during the last two years. Mr. Kirkland will continue his association with the Company as a project consultant.